aptorumgroup.com - APM Real Price to Acquire Entire Company

Brandmark of Aptorum Group (APM)

Aptorum Group Limited (APM) lacks market influence due to a lack of regular sales, and its valuation, which stands at -3.60 on the GURU.Markets platform, is sustained by news flow. The market price, as confirmed by this chart, coincides with environmental initiatives focused on laboratory cleanup and energy efficiency. The business relies on a model of selling innovation rights to industry behemoths, allowing the company to advance R&D without incurring manufacturing costs.

APM Aptorum Group Limited: Enterprise Value in the range 11/23/2025 - 07/20/2026

Analytical breakdowns for Aptorum Group Limited

- price and consensus price forecast:
Quote Chart Aptorum Group Ltd|APM - Price Target Chart
- market capitalization data:
Market Valuation Aptorum Group|APM - Total Company Value
- book capitalization data:
Share Book Value Aptorum Group|APM - Book Capitalization|Market Value to Book Value aptorumgroup.com|APM - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Aptorum Group Limited|APM - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Aptorum Group Ltd|APM - Company Debts|Debt to Book Value Aptorum Group
Fundamental company valuation:APM (Aptorum Group Limited)
Manufactured products of Aptorum

The investment attractiveness of Aptorum Group Limited is based on the potential of its patent portfolio in oncology and infectious diseases. The Enterprise Value metric determines the total cost of acquiring the business by summing market capitalization and net debt. By analyzing the Enterprise Value market valuation, an investor sees the real price of the asset without liquidity distortions. For biotech, this metric reflects the value of intellectual property. This chart's dynamics help assess the capitalization efficiency of future licensing deals.

Who Aptorum Group Limited competes with

Haleon PLC - Full Business Value|KVUE: Total Company Value|VRNA: Real Price to Acquire Entire Company|Total Company Value Jyong Biotech Ltd (MENS)|ligand.com (LGND) - Full Business Value|AMRX - Enterprise Value|Value Adjusted for Debt and Cash Perrigo Company PLC|Enterprise Value ALVO|Enterprise Value LQDA (Liquidia Inc.)|Total Company Value Galapagos NV|anipharmaceuticals.com - Value Adjusted for Debt and Cash|MNKD: Total Company Value|AMPH - Real Price to Acquire Entire Company|PCRX: Enterprise Value|Enterprise Value ARS Corp|TBPH - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash AQST|scPharmaceuticals Inc. - Total Company Value|Total Enterprise Value tectonictx.com TECX|Real Price to Acquire Entire Company Tonix Pharmaceuticals Inc. (TNXP)|Aggregate Business Value SXT Pharmaceuticals SXTC|Enterprise Value Eupraxia Pharma (EPRX)|BHST - Value Adjusted for Debt and Cash|Enterprise Value EXOZ|ORMP (Oramed Pharmaceuticals Inc.) - Total Enterprise Value|ENTX - Total Company Value|Value Adjusted for Debt and Cash MindWalk Therapeutics|Enterprise Value ABVC|Enterprise Value CPIX (cumberlandpharma.com)|Quantum BioPharma (QNTM) - Total Company Value|FGEN - Full Business Value|Real Price to Acquire Entire Company Telomir Pharma TELO|RANI: Aggregate Business Value|Total Company Value SNYR|RLYB (Rallybio) - Total Enterprise Value|LEXX - Total Company Value|Value Adjusted for Debt and Cash Pulmatrix Inc (PULM)|Real Price to Acquire Entire Company PTHL|Enterprise Value LYRA (Lyra Therapeutics Inc)|Impact BioMedical - Total Company Value|TNFA - Real Price to Acquire Entire Company|Real Price to Acquire Entire Company cbdMD Corp (YCBD)|PRFX - Value Adjusted for Debt and Cash|Enterprise Value CYTO (altamiratherapeutics.com)|LIPO (Lipella Pharma) - Full Takeover Company Value|OPTN - Total Company Value|Value Adjusted for Debt and Cash PIRS|Procaps - Total Company Value|Total Enterprise Value Petros Pharmaceuticals Inc PTPI|Real Price to Acquire Entire Company QLI (Qilian International Holding Group Limited)|ACELYRIN Inc. - Enterprise Value|Total Company Value TFF Pharmaceuticals